1. Edwards et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006. Dostupné na: http://www.cdc.gov/ncidod/dhqp/nhsn_documents.html.
2. Gastmeier, P., Zuschneid, I., Geffers, C. Antimicrobially impregnated catheters: An overview of randomized controlled trials. Journal of Vascular Access, 2003, 4, 3, p. 102–110.
3. Horan, T. C., Gaynes, R. Surveillance of nosocomial infections. In Mayhall, C. G., ed. Hospital Epidemiology and Infection Control. Philadelphia: Lippincott Williams & Wilkins, 2004, p.1659–1702.
4. Černý, V. et al. Sepse v intenzivní péči. 2. vyd., 2005, p. 28–29.
5. Morales, M. et al. Biofilm: the microbial “bunker” for intravascular catheter-related infection. Support Care Cancer, 2004, 12, p. 701–707.
6. Růžička, F. Biofilm a jeho význam. In Kurz antibiotické terapie. Praha, 2005.
7. Modak, S. M., Sampath, L. Development and evaluation of a new polyurethane central venous antisepstic catheter. Complications Surg., 1992, 11, p. 23–29.
8. Richards, B. et al. Effect of central venous catheter type on infections: a prospective clinical trial. The Journal of Hospital Infection, 2003, 54, 1, p. 10–17.
9. van Vliet, J. et al. A comparison between two types of central venous catheters in the prevention of catheter-related infections: The importance of performing all the relevant cultures. Clinical Intensive Care, 2001, 12, 3, p. 135–140.
10. Tennenberg, S. et al. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Archives of Surgery, 1997, 132, 12, p. 1348–1351.
11. Logghe, C. et al. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. The Journal of Hospital Infection, 1997, 37, 2, p. 145–156.
12. Ciresi, D. L. et al. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. The American Surgeon, 1996, 62, 8, p. 641–646.
13. Sheng, W. H. et al. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagnostic Microbiology and Infectious Disease, 2000, 38, 1, p. 1–5.
14. Dunser, M. W. et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesthesia and Analgesia, 2005, 101, 6, p. 1778–1784.
15. Maki, D. G. et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Annals of Internal Medicine, 1997, 127, 4, p. 257–266.
16. Brun-Buisson, C. et al. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Medicine, 2004, 30, 5, p. 837–843.
17. Rupp, M. E. et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Annals of Internal Medicine, 2005, 143, 8, p. 570–580.
18. Ostendorf, T. et al. Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients – A double-blind, randomised, prospective, controlled trial. Supportive Care in Cancer, 2005, 13, 12, p. 993–1000.
19. Stephens, R. et al. Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. British Journal of Anaesthesia, 2001, 87, 2, p. 306–308.
20. Raad, I. et al. Antibiotics and prevention of microbial colonization of catheters. Antimicrobial Agents and Chemotherapy, 1995, 39, 11, p. 2397–2400.
21. Leon, C. et al. Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Medicine, 2004, 30, 10, p. 1891–1899.
22. Darouiche, R. O. et al. A comparison of two antimicrobial-impregnated central venous catheters. New England Journal of Medicine, 1999, 340, 1, p. 1–8.
23. Fraenkel, D. et al. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Critical Care Medicine, 2006, 34, 3, p. 668–675.
24. Falagas, M. E. et al. Rifampicin-impregnated central venous catheters: A meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2007, 59, 3, p. 359–369.
25. Niël-Weise, B. S., Stijnen, T., van den Broek, P. J. Anti-infective-treated central venous catheters: a systematic review of randomized controlled trials. Intensive Care Med., 2007, 12, 33, p. 2058–2068.
26. Guggenbichler, J.-P. et al. A New Technology of Microdispersed Silver in Polyurethane Induces Antimicrobial Activity in Central Venous Catheters. Infection, 1999, 27, Suppl. 1, p. S16–S23.
27. Bechert, T. et al. The Erlanger Silver Catheter: In Vitro Results for Antimicrobial Activity. Infection, 1999, 27, Suppl. 1, p. S24–S29.
28. Boswald, M. et al. Reduced rates of catheter-associated infection by use of a new silver-impregnated central venous catheter. Infection, 1999, 27, Suppl. 1, p. S56–60.
29. Goldschmidt, H. et al. Prevention of catheter-related infections by silver coated central venous catheters in oncological patients. Zentralblatt für Bakteriologie : International Journal of Medical Microbiology, 1995, 283, 2, p. 215–223.
30. Furno, F. et al. Silver nanoparticles and polymeric medical devices: a new approach to prevention of infection? J. Antimicrob. Chemother., 2004, 54, p. 1019–1024.
31. Moretti, E. W. et al. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. The Journal of Hospital Infection, 2005, 61, 2, p. 139–145.
32. Yorganci, K. et al. In Vitro Evaluation of the Antibacterial Activity of Three Different Central Venous Catheters Against Gram-Positive Bacteria. Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21, p. 379–384.
33. Ranucci, M. et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit. Care Med., 2003, 31, 1, p. 52–59.
34. Kalfon, P. et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit. Care Med., 2007, 35, 4, p. 1032–1039.
35. Walz, J. M. et al. A multicenter randomized controlled clinical trial comparing central venous catheters impregnated with either 5-Fluorouracil or chlorhexidine/silver sulfadiazine in preventing catheter colonization. 28th International Symposium on Intensive Care and Emergency Medicine, Brussels, March 18-21, 2008.
36. Scott, A. et al. Do Antimicrobial-Impregnated Central Venous Catheters Prevent Catheter-Related Bloodstream Infection? Clinical Infectious Diseases, 2003, 37, p. 65–72.
37. Crnich, C. J., Maki, D. G. Are antimicrobial-impregnated catheters effective? Don’t throw out the baby with the bathwater. Clin. Infect. Diseases, 2004, 38, 9, p. 1287–1292.
38. Carrasco, M. N. et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Medicine, 2004, 30, 4, p. 633–638.
39. Collin, G. R. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. Chest, 1999, 115, 6, p. 1632–1640.
40. Cicalini, S., Palmieri, F., Petrosillo, N. Clinical review: New technologies for prevention of intravascular catheter-related infections. Critical Care, 2004, 8, 3, p. 157–162.
41. Eggimann, P. Prevention of intravascular catheter infection. Current Opinion in Infectious Diseases, 2007, 20, 4, p. 360–369.
42. O’Grady, N. et al. Guidelines for the prevention of intravascular catheter-related infections. Infection Control and Hospital Epidemiology, 2002, 23, 12, p. 759–769.